About Revance Therapeutics (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:RVNC
- CUSIP: N/A
- Web: www.revance.com
- Market Cap: $785.88 million
- Outstanding Shares: 30,819,000
- 50 Day Moving Avg: $25.96
- 200 Day Moving Avg: $23.68
- 52 Week Range: $12.35 - $28.75
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.54
- P/E Growth: -0.62
- Annual Revenue: $300,000.00
- Price / Sales: 2,619.62
- Book Value: $5.24 per share
- Price / Book: 4.87
- EBITDA: ($89,740,000.00)
- Net Margins: -32,936.67%
- Return on Equity: -55.21%
- Return on Assets: -47.75%
- Current Ratio: 7.94%
- Quick Ratio: 7.94%
- Average Volume: 148,394 shs.
- Beta: 1.64
- Short Ratio: 23.45
Frequently Asked Questions for Revance Therapeutics (NASDAQ:RVNC)
What is Revance Therapeutics' stock symbol?
Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."
How were Revance Therapeutics' earnings last quarter?
Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.93) by $0.03. The firm earned $0.08 million during the quarter, compared to analysts' expectations of $0.05 million. Revance Therapeutics had a negative net margin of 32,936.67% and a negative return on equity of 55.21%. Revance Therapeutics's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.88) earnings per share. View Revance Therapeutics' Earnings History.
Where is Revance Therapeutics' stock going? Where will Revance Therapeutics' stock price be in 2017?
4 brokerages have issued 12 month target prices for Revance Therapeutics' shares. Their predictions range from $28.00 to $50.00. On average, they expect Revance Therapeutics' share price to reach $37.00 in the next twelve months. View Analyst Ratings for Revance Therapeutics.
What are analysts saying about Revance Therapeutics stock?
Here are some recent quotes from research analysts about Revance Therapeutics stock:
- 1. According to Zacks Investment Research, "Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. " (10/11/2017)
- 2. Cantor Fitzgerald analysts commented, "Today Revance announced that Mark Foley has been appointed to the Board of Directors, effective 9/5/17." (9/6/2017)
Who are some of Revance Therapeutics' key competitors?
Some companies that are related to Revance Therapeutics include Radius Health (RDUS), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), Clinigen Group PLC (CLIN), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), NeuroDerm (NDRM), REGENXBIO (RGNX), Xencor (XNCR), Epizyme (EPZM), Athenex (ATNX), Retrophin (RTRX) and Amarin Corporation PLC (AMRN).
Who are Revance Therapeutics' key executives?
Revance Therapeutics' management team includes the folowing people:
- Angus Charles Russell, Independent Chairman of the Board
- L. Daniel Browne, Co-Founder, President, Chief Executive Officer, Director
- Lauren P. Silvernail, Chief Financial Officer, Chief Business Officer
- Abhay Joshi Ph.D., Chief Operating Officer
- Todd E. Zavodnick, Chief Commercial Officer and President, Aesthetics & Therapeutics
- Mark J. Foley, Director
- Robert F. Byrnes, Independent Director
- Julian S. Gangolli, Independent Director
- Phyllis I. Gardner M.D., Independent Director
- Philip J. Vickers, Independent Director
How do I buy Revance Therapeutics stock?
Shares of Revance Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Revance Therapeutics' stock price today?
MarketBeat Community Rating for Revance Therapeutics (NASDAQ RVNC)MarketBeat's community ratings are surveys of what our community members think about Revance Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Revance Therapeutics stock can currently be purchased for approximately $25.50.
Consensus Ratings for Revance Therapeutics (NASDAQ:RVNC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$37.00 (45.10% upside)|Consensus Price Target History for Revance Therapeutics (NASDAQ:RVNC)
Analysts' Ratings History for Revance Therapeutics (NASDAQ:RVNC)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/26/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$50.00||High|
|8/22/2017||JMP Securities||Initiated Coverage||Mkt Outperform -> Outperform||$34.00||Medium|
|7/26/2017||Piper Jaffray Companies||Set Price Target||Buy||$28.00||Low|
|8/5/2016||Brean Capital||Reiterated Rating||Hold||N/A|
|6/14/2016||SunTrust Banks, Inc.||Lower Price Target||Buy||$46.00 -> $22.00||N/A|
|12/30/2015||Cowen and Company||Reiterated Rating||Buy||N/A|
|11/10/2015||William Blair||Reiterated Rating||Buy||$59.00||N/A|
Earnings History for Revance Therapeutics (NASDAQ:RVNC)Earnings History by Quarter for Revance Therapeutics (NASDAQ RVNC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||($0.93)||($0.90)||$0.05 million||$0.08 million||View||Listen|
|5/9/2017||Q1 2017||($0.84)||($0.94)||$0.07 million||$0.08 million||View||Listen|
|2/27/2017||Q416||($0.84)||($0.95)||$0.07 million||$0.08 million||View||Listen|
|11/3/2016||Q316||($0.89)||($0.64)||$0.08 million||$0.08 million||View||N/A|
|8/4/2016||Q216||($0.86)||($0.88)||$0.06 million||$0.80 million||View||N/A|
|5/9/2016||Q1||($0.83)||($0.71)||$0.08 million||$0.08 million||View||Listen|
|3/2/2016||Q415||($0.86)||($0.83)||$0.09 million||$0.08 million||View||Listen|
|11/9/2015||Q315||($1.01)||($0.81)||$0.10 million||$0.08 million||View||N/A|
|8/6/2015||Q415||($0.84)||($0.71)||$0.15 million||$0.08 million||View||N/A|
|5/13/2015||Q1||($0.69)||($0.65)||$0.15 million||$0.08 million||View||Listen|
|3/2/2015||($0.53)||($0.60)||$0.08 million||$0.08 million||View||N/A|
|5/13/2014||Q1 14||($0.87)||($1.93)||$0.16 million||View||N/A|
Earnings Estimates for Revance Therapeutics (NASDAQ:RVNC)
2017 EPS Consensus Estimate: ($3.80)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Revance Therapeutics (NASDAQ:RVNC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Revance Therapeutics (NASDAQ:RVNC)
Insider Ownership Percentage: 18.86%Insider Trades by Quarter for Revance Therapeutics (NASDAQ:RVNC)
Institutional Ownership Percentage: 89.32%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/18/2017||L Daniel Browne||CEO||Sell||7,662||$26.16||$200,437.92|| |
|10/12/2017||Lauren P Silvernail||CFO||Sell||11,164||$26.67||$297,743.88|| |
|9/20/2017||L Daniel Browne||CEO||Sell||7,600||$23.58||$179,208.00|| |
|8/23/2017||L Daniel Browne||CEO||Sell||22,800||$22.76||$518,928.00|| |
|5/24/2017||L Daniel Browne||CEO||Sell||19,713||$20.35||$401,159.55|| |
|5/22/2017||L Daniel Browne||CEO||Sell||12,287||$20.20||$248,197.40|| |
|5/22/2017||Lauren P Silvernail||CFO||Sell||1,793||$20.20||$36,218.60|| |
|1/25/2017||L Daniel Browne||CEO||Sell||12,000||$19.78||$237,360.00|| |
|12/28/2016||L Daniel Browne||CEO||Sell||12,000||$20.94||$251,280.00|| |
|11/25/2016||L Daniel Browne||CEO||Sell||12,000||$17.92||$215,040.00|| |
|10/26/2016||L Daniel Browne||CEO||Sell||12,000||$14.85||$178,200.00|| |
|6/13/2016||Curtis Ruegg||EVP||Sell||1,000||$18.25||$18,250.00|| |
|5/9/2016||Curtis Ruegg||EVP||Sell||1,000||$16.18||$16,180.00|| |
|4/11/2016||Curtis Ruegg||EVP||Sell||1,000||$19.11||$19,110.00|| |
|3/7/2016||Curtis Ruegg||EVP||Sell||1,000||$20.43||$20,430.00|| |
|2/8/2016||Curtis Ruegg||EVP||Sell||1,000||$18.14||$18,140.00|| |
|1/6/2016||Curtis Ruegg||EVP||Sell||2,000||$33.06||$66,120.00|| |
|11/17/2015||Arthur Peter Bertolino||EVP||Sell||7,753||$39.11||$303,219.83|| |
|8/17/2015||Curtis Ruegg||EVP||Sell||3,000||$30.33||$90,990.00|| |
|7/17/2015||Curtis Ruegg||EVP||Sell||3,000||$31.03||$93,090.00|| |
|6/17/2015||Curtis Ruegg||EVP||Sell||3,000||$33.53||$100,590.00|| |
|5/18/2015||Curtis Ruegg||EVP||Sell||3,000||$26.42||$79,260.00|| |
|4/17/2015||Curtis Ruegg||EVP||Sell||2,000||$22.23||$44,460.00|| |
|3/17/2015||Curtis Ruegg||EVP||Sell||1,500||$18.61||$27,915.00|| |
|3/9/2015||Curtis Ruegg||EVP||Sell||500||$18.00||$9,000.00|| |
|2/17/2015||Curtis Ruegg||EVP||Sell||1,000||$16.80||$16,800.00|| |
|1/20/2015||Curtis Ruegg||EVP||Sell||1,000||$17.25||$17,250.00|| |
|12/17/2014||Curtis Ruegg||EVP||Sell||1,000||$16.45||$16,450.00|| |
|11/28/2014||L Daniel Browne||CEO||Buy||6,000||$16.67||$100,020.00|| |
|11/18/2014||Curtis Ruegg||EVP||Sell||1,000||$16.00||$16,000.00|| |
|9/17/2014||Curtis Ruegg||EVP||Sell||2,000||$20.55||$41,100.00|| |
|9/17/2014||Jacob Waugh||Insider||Sell||97,713||$20.73||$2,025,590.49|| |
Headline Trends for Revance Therapeutics (NASDAQ:RVNC)
Latest Headlines for Revance Therapeutics (NASDAQ:RVNC)
Loading headlines, please wait.
Revance Therapeutics (RVNC) Chart for Monday, October, 23, 2017